Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAYNIER MOYA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1124288980
CMS profile
278302
Location
PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,741.44

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,741.44 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Chiesi USA, Inc. $1,741.44 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAYNIER MOYA

NPI 1124288980 · CMS profile ID 278302

Allopathic & Osteopathic Physicians / Internal Medicine

PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JAYNIER MOYA, NPI 1124288980, CMS profile ID 278302, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1124288980?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $1,741.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Chiesi USA, Inc. $870.7201/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050859851 CMS
Chiesi USA, Inc. $870.7201/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051592383 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $128.50 2
PY2023 $1,741.44 2
PY2025 $15.30 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,567,242.14 108
PY2024 Recipient $1,161.49 6
PY2024 Principal investigator $5,059,140.87 296
PY2023 Recipient $2,506.25 1
PY2023 Principal investigator $14,127,127.37 743
PY2022 Recipient $24,618.00 1
PY2022 Principal investigator $15,001,316.81 131
PY2021 Principal investigator $6,255,399.36 48
PY2020 Principal investigator $653,923.11 62
PY2019 Principal investigator $748,551.83 218

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

108 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $22,607.00 12/22/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1226122204
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,687.00 12/11/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040161
Principal investigator 1 ModernaTX, Inc. $86,483.28 11/24/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953677
Principal investigator 1 ModernaTX, Inc. $45,919.86 11/24/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953681
Principal investigator 1 ModernaTX, Inc. $7,886.15 11/24/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953685
Principal investigator 1 ModernaTX, Inc. $1,468.58 11/24/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953689
Principal investigator 1 ModernaTX, Inc. $3,281.85 11/24/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953693
Principal investigator 1 ModernaTX, Inc. $9,081.88 11/24/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953695
Principal investigator 1 ModernaTX, Inc. $3,407.14 11/24/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953697
Principal investigator 1 ModernaTX, Inc. $20,266.92 11/24/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953703
Principal investigator 1 ModernaTX, Inc. $8,951.25 11/24/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953705
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,841.00 11/13/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040159
Principal investigator 1 SANOFI US SERVICES INC. $13,053.00 10/27/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1226122148
Principal investigator 1 SANOFI US SERVICES INC. $12,906.40 10/20/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226122141
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,678.50 10/14/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040157
Principal investigator 1 SANOFI US SERVICES INC. $11,156.80 10/06/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226122128
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,943.50 09/17/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040155
Principal investigator 1 SANOFI US SERVICES INC. $12,906.40 09/15/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226122092
Principal investigator 1 SANOFI US SERVICES INC. $31,159.00 09/15/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226122099
Principal investigator 1 ModernaTX, Inc. $4,800.00 09/03/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953691
Principal investigator 1 SANOFI US SERVICES INC. $6,701.37 08/25/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226122096
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,841.00 08/19/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040153
Principal investigator 1 SANOFI US SERVICES INC. $18,994.40 08/18/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226122063
Principal investigator 1 SANOFI US SERVICES INC. $640.00 08/11/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226122067
Principal investigator 1 SANOFI US SERVICES INC. $10,580.40 08/11/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226122075
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 08/08/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198834
Principal investigator 1 Janssen Research & Development, LLC $8,831.00 08/08/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198938
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,950.00 08/06/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040151
Principal investigator 1 SANOFI US SERVICES INC. $6,168.00 08/04/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1226122050
Principal investigator 1 SANOFI US SERVICES INC. $63,700.00 07/28/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226122040
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,189.50 07/24/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040147
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,950.00 07/24/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040149
Principal investigator 1 SANOFI US SERVICES INC. $21,927.00 07/21/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1226122030
Principal investigator 1 SANOFI US SERVICES INC. $6,088.00 07/14/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121968
Principal investigator 1 SANOFI US SERVICES INC. $38,280.80 07/14/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226122014
Principal investigator 1 Chiesi USA, Inc. $1,000.00 07/09/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234404049
Principal investigator 1 Chiesi USA, Inc. $500.00 07/09/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234404053
Principal investigator 1 Chiesi USA, Inc. $5,000.00 07/09/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234404058
Principal investigator 1 Chiesi USA, Inc. $1,000.00 07/09/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234404063
Principal investigator 1 Chiesi USA, Inc. $1,000.00 07/09/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234404067
Principal investigator 1 Chiesi USA, Inc. $1,000.00 07/09/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234404071
Principal investigator 1 Chiesi USA, Inc. $500.00 07/09/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1234404074
Principal investigator 1 SANOFI US SERVICES INC. $50.00 07/07/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226121948
Principal investigator 1 SANOFI US SERVICES INC. $200.00 07/07/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226121952
Principal investigator 1 SANOFI US SERVICES INC. $1,600.00 07/07/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226121961
Principal investigator 1 SANOFI US SERVICES INC. $14,800.00 07/07/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226121964
Principal investigator 1 SANOFI US SERVICES INC. $3,360.00 07/07/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226121972
Principal investigator 1 SANOFI US SERVICES INC. $15,585.00 07/07/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226121976
Principal investigator 1 SANOFI US SERVICES INC. $714.44 07/07/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226121980
Principal investigator 1 SANOFI US SERVICES INC. $23,420.00 07/07/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226121985
Principal investigator 1 SANOFI US SERVICES INC. $15,688.40 07/02/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121956
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,942.50 06/24/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040145
Principal investigator 1 SANOFI US SERVICES INC. $10,850.00 06/23/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226121940
Principal investigator 1 SANOFI US SERVICES INC. $10,270.00 06/23/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226121944
Principal investigator 1 Janssen Research & Development, LLC $3,844.00 06/20/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198812
Principal investigator 1 Janssen Research & Development, LLC $21,249.00 06/16/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198807
Principal investigator 1 GlaxoSmithKline, LLC. $63,105.80 06/11/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1192170921
Principal investigator 1 Janssen Research & Development, LLC $8,171.00 06/10/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198892
Principal investigator 1 SANOFI US SERVICES INC. $42,700.60 06/09/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226121929
Principal investigator 1 Janssen Research & Development, LLC $12,136.00 06/04/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198842
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $33,329.49 05/28/2025 Non-covered Recipient Entity
Elias Research Associates Llc
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia No dispute reported 06/30/2026 1235997553
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,097.50 05/22/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040143
Principal investigator 1 Janssen Research & Development, LLC $149,585.00 05/20/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198865
Principal investigator 1 Janssen Research & Development, LLC $245,520.00 05/13/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198922
Principal investigator 1 Janssen Research & Development, LLC $846,950.00 05/12/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198949
Principal investigator 1 SANOFI US SERVICES INC. $25,036.00 05/12/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226121926
Principal investigator 1 SANOFI US SERVICES INC. $7,452.00 05/05/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226121916
Principal investigator 1 SANOFI US SERVICES INC. $14,160.00 05/05/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226121919
Principal investigator 1 SANOFI US SERVICES INC. $29,606.00 05/05/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1226121922
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,800.00 04/30/2025 Non-covered Recipient Entity
AVICENNA DM CLINICAL RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185545947
Principal investigator 1 SANOFI US SERVICES INC. $35,902.80 04/28/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121912
Principal investigator 1 Janssen Research & Development, LLC $69,300.00 04/24/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198957
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $23,744.50 04/24/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040141
Principal investigator 1 Janssen Research & Development, LLC $1,272.00 04/22/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198818
Principal investigator 1 Janssen Research & Development, LLC $4,440.00 04/22/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198858
Principal investigator 1 Janssen Research & Development, LLC $1,350.00 04/22/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198873
Principal investigator 1 Janssen Research & Development, LLC $245,155.00 04/22/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198883
Principal investigator 1 Janssen Research & Development, LLC $4,680.00 04/22/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198908
Principal investigator 1 Janssen Research & Development, LLC $29,403.00 04/16/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198878
Principal investigator 1 ModernaTX, Inc. $1,980.00 04/16/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953675
Principal investigator 1 Janssen Research & Development, LLC $5,280.00 04/15/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198931
Principal investigator 1 Janssen Research & Development, LLC $420.00 04/10/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198849
Principal investigator 1 SANOFI US SERVICES INC. $37,492.70 04/07/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226121903
Principal investigator 1 SANOFI US SERVICES INC. $45,278.40 04/02/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121884
Principal investigator 1 SANOFI US SERVICES INC. $70,081.30 04/02/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226121888
Principal investigator 1 Janssen Research & Development, LLC $28,665.00 03/24/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198900
Principal investigator 1 SANOFI US SERVICES INC. $58,771.00 03/24/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1226121890
Principal investigator 1 ModernaTX, Inc. $7,800.00 03/21/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953673
Principal investigator 1 ModernaTX, Inc. $8,850.00 03/21/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953679
Principal investigator 1 ModernaTX, Inc. $9,600.00 03/21/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953687
Principal investigator 1 ModernaTX, Inc. $2,550.00 03/21/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953699
Principal investigator 1 ModernaTX, Inc. $1,400.00 03/20/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953701
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,198.00 03/20/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040139
Principal investigator 1 SANOFI US SERVICES INC. $30,603.90 03/17/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226121900
Principal investigator 1 GlaxoSmithKline, LLC. $4,500.00 03/14/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1192170917
Principal investigator 1 GlaxoSmithKline, LLC. $36,848.00 03/14/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT No dispute reported 06/30/2026 1192170925
Principal investigator 1 SANOFI US SERVICES INC. $2,484.00 03/04/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226121872
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $33,689.50 02/27/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040165
Principal investigator 1 AstraZeneca Pharmaceuticals LP $196,104.50 02/26/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER, LLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185545945
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/21/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040297
Principal investigator 1 Janssen Research & Development, LLC $6,300.00 02/19/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198916
Principal investigator 1 SANOFI US SERVICES INC. $67,790.60 02/18/2025 Non-covered Recipient Entity
Pines Care Research Center Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226121898
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20,065.50 01/30/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244040163
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,650.00 01/22/2025 Non-covered Recipient Entity
VIDA MEDICAL CENTERS PEMBROKE PINE
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study) No dispute reported 06/30/2026 1190313087
Principal investigator 1 Janssen Research & Development, LLC $3,150.00 01/21/2025 Non-covered Recipient Entity
Pines Care Rsrch Ctr
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175198826
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $168,172.21 01/17/2025 Non-covered Recipient Entity
Pines Care Research Center, Llc
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia No dispute reported 06/30/2026 1235994595
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $65,515.92 01/06/2025 Non-covered Recipient Entity
Pines Care Research Center, Llc
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) No dispute reported 06/30/2026 1235994593
Principal investigator 1 ModernaTX, Inc. $9,000.00 01/06/2025 Non-covered Recipient Entity
PINES CARE RESEARCH CENTER LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252953683